apy alone holds a potential for cure for few patients, and local recurrences are even more frequent.9-1' Nevertheless, in a palliative situation external radiotherapy can improve symptoms and survival time.
For patients who cannot be treated by surgery or external radiotherapy, local treatment of bronchial occlusion may be beneficial. Apart from Nd-YAG laser therapy and endoluminal prosthesis,12" 3 brachytherapy is being used increasingly for the treatment of these subgroups of patients.14 Initially low dose rates15-17 prevailed in brachytherapy and are now replaced by high-dose rates (HDRs).18"l9 Remote HDR afterloading brachytherapy with iridium 192 ('92Ir) improves the effectiveness of local disease control. 20 Moreover, HDR brachytherapy offers a convenient form of therapy owing to a short irradiation time which makes treatment on an outpatient basis possible.
For better results, we believed that fractionation schemes and total dose needed to be optimized.21 Therefore 26 weeks. This finding indicates a trend, but in both groups median survival was almost equal (19 vs 18 weeks), so no significant probability level was reached (Fig 1) .
This result remained stable, when only those patients who were treated according to protocol were analyzed. In group 1 median survival increased slightly to 20 weeks (mean, 30 weeks), whereas the median survival time in group 2 was 24 weeks (mean, Weeks FIGURE 1. Survival in groups 1 and 2, Kaplan-Meier-plot; in group 1, 4 patients were censored, and in group 2, 10 patients were censored. Mean survival in group 1 was 26 weeks and in group 2, it was 49 weeks. cases, with almost equal numbers in both groups. If the study population is analyzed on a protocol basis, bleeding from cancer was 31.8% (7 patients) in group 1 and 17.2% (5 patients) in group 2. These differences are not significant yet. Survival time in relation to causes of death is shown in Table 3 . Although no difference reaches significance, a trend may be seen for shorter median but not mean survival in group II regarding the time span until bleeding occurred from the tracheobronchial tree.
Local Tumor Control
Local tumor control was assessed 3 months after the end of the treatment. Out of 93 patients, 73 (79%) could be evaluated at this time. Some patients dropped out due to early death within the first three months. Complete remission was seen in one patient in group 1. The criteria for partial remission were met by 15 (41.6) Likewise, if we looked for changes in survival or episodes of bleeding in patients receiving irradiation at an average of at least 10 weeks after source replacement, there were no significant differences.
DISCUSSION
The results presented are based on a study population of 93 patients with far advanced lung cancer. Our investigation shows no disadvantage for the fractionation regimen employing 2 times 7.2 Gy with a 3-week interval when compared with a more fractionated schedule (4X3.8 Gy weekly). Survival time in the group receiving two applications is not significantly higher than with the more fractionated schedule, but the trend toward longer survival is obvious. Local disease control and side effects are similar in both groups. The distribution of sex and age in our study groups reflects the general distribution in larger series of lung cancers.1"3 An important prognostic factor for survival time of patients is their KPS during treatment. In a previous study,26 it was shown that a KPS lower than 90 is a most unfavorable parameter regarding survival. In our study, only one of our patients had a KPS of 90 at the beginning of the study (at the end of treatment there were five patients). This could explain the short overall survival time. The mean KPS improved moderately after treatment. This indicates the lack of serious acute side effects of this treatment modality. Furthermore, the improvement of local tumor control also improves the general well-being of our patients.
Regarding the types of histologic characteristics of the trial patients, again the distribution is almost the same as in the larger series of lung cancer patients. We accepted every kind of histologic feature because in this late stage of cancer disease local treatment of every kind of tumor often is necessary, regardless of the potentially higher malignancy of some cell types. In both groups, the number of squamous cell carcinoma was exactly the same, about 50% of the patients. As comparable with the whole population, we analyzed survival in this subgroup. In contrast to the overall result obtained, group 1 had a higher median survival. Explanation of this finding is difficult because studies about tumor cell biology regarding the influence of cell type and method of radiation are missing. We tried to do a meta-analysis of previous studies in terms of survival time, type of radiation, and tumor cell type. However, histologic typing is seldom specified, so retrospective conclusions are not possible.
Small cell tumors in general have a shorter survival time than the other carcinomas.27 In our study, small cell tumors were more frequent in group 1. However, if survival was analyzed with or without this subgroup, no change was found in group 1. Nevertheless, there was a slight deterioration of survival in group 2 if oat cell tumors were dropped. This shows that there is no significant effect of the histologic findings on survival or cause of death in our study population.
To exclude another possible bias, we looked at the tumor stage at the beginning of our study. Almost all patients had a far advanced tumor stage. This is of course related to our inclusion criteria, that no other treatment modalities were suitable at the beginning of our study. Furthermore, about 90% had undergone prior treatments. Median survival time in our patients was about 4.5 months, not even half a year. This demonstrates one crucial point for studies like this. It is difficult to detect an unequivocal difference comparing treatment regimens when patients are studied who have a relatively short survival time. It can be assumed, though, that dying without therapy would be quite faster and more painful, especially in lung cancer. Other studies27-33 and this one show clearly that good local control of the tumor can be obtained for a reasonably long time (in relation to the survival time left), and that some treatment modalities even seem to improve survival time. Median survival in the previously mentioned studies ranged from 2 to 10 months, but influencing variables are not shown. This improvement in survival time for one of the treatment regimens cannot be shown in our study on a large series of patients. However, we can make a statement about the required dose and fractionation in end-stage central lung cancer: two irradiations with two times 7.2 Gy are enough to obtain the same or even a better result compared with four times half the dose.
The most important potential side effect of brachytherapy seems to be fatal hemoptysis. In some previous studies,34-39 causes of death are shown, but the occurrence of fatal hemoptysis is considered as a complication of treatment and not related to the disease itself. It is not clear if the incidence of lethal hemoptysis is related, for example, to tumor invasion into pulmonary vessels or related to the administered irradiation dose and fractionation regimen. Following Cox et Speiser and Spratling20 recently published a study with a large series of patients in order to find the optimum dose and fractionation in brachytherapy for central lung cancer. They treated their patients without randomization. Different treatment regimens were tested subsequently with three levels of brachytherapy doses. Regardless of the limitations of their methods their conclusion is that the most effective dose and fractionation is 7.5 Gy in a 10-mm depth for 3 fractions once a week. There was no difference in survival time (median survival from first treatment, about 25 weeks) in all three treatment groups. To our group 2, only 66% of the preferred treatment dose of Speiser and Spratling20 was applied (2X7.2 Gy), but median survival time is comparable. We conclude that two fractions of 7.2 Gy is enough to obtain reasonable local control until the death of the patient and that more treatment would induce more possible side effects, increase treatment cost, and be more inconvenient for patients.
CONCLUSION
In this prospective and randomized study, 93 patients were evaluated and distributed in two treatment groups, one receiving 15.4 Gy in 4 fractions of 3.8 Gy and, the other receiving 14.4 Gy in 2 fractions of 7.2 Gy. The overall survival is slightly better for group 2, but median survival time is the same. Local control is a little better in group 1, but this has no influence on survival time. Occurrence of fatal hemorrhages also is equal in both groups, depending on the types of histologic findings.
At present, we can show that brachytherapy for central lung tumors with palliative intent can be done with good results regarding survival and local control with only two sessions of 7.2 Gy each. This seems to be the most convenient and safest treatment modality for patients with these tumors. This statement must be made with caution owing to the limited number of patients in our trial; comparison with other studies is difficult because of different study designs, applied dosages, and fractionation schedules.
